Recombinant Human CDK4 Protein，His

CDK4 (Cyclin-Dependent Kinase 4) is a pivotal regulatory enzyme in the cell cycle, primarily responsible for driving the transition from the G1 phase to the S phase, thus facilitating cellular proliferation. Its activity is modulated by association with cyclin D and is critical for executing mitogenic signals. Dysregulation of CDK4 is frequently associated with various cancers, as overexpression or mutations can lead to uncontrolled cell division. Consequently, CDK4 has emerged as a significant target for therapeutic intervention in cancer treatment. The study of recombinant CDK4 proteins allows researchers to investigate the enzyme's structure, function, and interactions at a molecular level. This recombinant approach provides purified CDK4 for in vitro assays, enabling the exploration of its enzymatic activity, binding partners, and the effects of potential inhibitors. Furthermore, understanding the kinetic properties and regulatory mechanisms governing CDK4 can offer insights into how cancer cells evade normal growth controls. With the advent of potent CDK4 inhibitors, such as palbociclib, understanding the molecular underpinnings of CDK4 function has become increasingly relevant for developing effective cancer therapies. Thus, the research on CDK4 recombinant proteins serves as a crucial component of efforts to delineate the intricacies of cell cycle regulation and devise novel strategies for cancer treatment.